Table 1 Characteristics of studies included in the systematic review
Study (reference) | Patients | Molecular marker | Ethnicity (Country) | Evaluation criteria | Sample size | Chemotherapeutic regimens | Outcomes |
|---|---|---|---|---|---|---|---|
Goekkurt 2006, [11] | Patients with advanced GC | TS, GSTs, MTHFR, ERCC1-118 | European (Germany) | RECIST | 52 | 5-Fu+cisplatin + leucovorin | RR and OS |
Ruzzo 2006 [14] | Patients with advanced GC | TS, GSTs, MTHFR, ERCC1-118 | European (Italy) | Others | 175 | fluorouracil/cisplatin | RR and OS |
Shim 2010 [17] | Patients with recurrent or metastatic GC | GSTs | Asian (Korea) | RECIST | 200 | Paclitaxel/docetaxel +cisplatin | RR and OS |
Park 2011 [18] | Patients with metastatic GC | ERCC1-118 | Asian (Korea) | RECIST | 108 | S-1 + cisplatin | RR and OS |
Han 2010 [19] | Patients with recurrent or metastatic GC | TS, ERCC1-118 | Asian (Korea) | RECIST | 38 | 5-Fu+leucovorin +oxaliplatin | RR and OS |
Stocker 2009 [20] | Neoadjuvant chemotherapy for locally advanced GC without distant metastasis | ERCC1-118 | European (Germany) | Others | 178 | 5-Fu+leucovorin +cisplatin | RR and OS |
Seo 2009 [21] | Patients with recurrent or metastatic GC | TS, GSTs, ERCC1-118 | Asian (Korea) | RECIST | 94 | 5-Fu+ oxaliplatin/irinotecan | RR, OS and toxicity |
Liu 2011 [22] | Patients with advanced GC | GSTs, ERCC1-118 | Asian (China) | NR | 126 | 5-FU+leucovorin +oxaliplatin | OS |
Ott 2008 [23] | Neoadjuvant chemotherapy for locally advanced GC without distant metastasis | GSTs | European (Germany) | Others | 139 | 5-Fu+leucovorin + cisplatin | RR and OS |
Li 2010 [24] | Patients with advanced GC | GSTs | Asian (China) | Others | 92 | 5-Fu +oxaliplatin | RR, OS and toxicity |
Lu 2004 [25] | Patients with advanced GC | MTHFR | Asian (China) | WHO | 75 | 5-Fu+leucovorin | RR and toxicity |
Huang 2009 [26] | Patients with GC after curative surgery | GSTs, ERCC1-118 | Asian (China) | NR | 102 | 5-Fu+leucovorin +oxaliplatin | OS |
Shitara 2010 [27] | Patients with inoperable GC | TS, MTHFR | Asian (Japan) | NR | 132 | 5-Fu et al. | OS and toxicity |
Huang 2009 [28] | Patients with GC after curative surgery | TS, MTHFR | Asian (China) | NR | 116 | 5-Fu+leucovorin et al. | OS |
Ishida 2002 [29] | Patients with GC after surgery | TS | Asian (Japan) | NR | 51 | 5-Fu et al. | OS |
Keam 2008 [30] | Patients with recurrent or metastatic GC | GSTs, ERCC1-118 | Asian (Korea) | WHO | 73 | 5-Fu+leucovorin +oxaliplatin | RR and OS |
Goekkurt 2009, [31] | Patients with advanced GC | TS, GSTs, MTHFR, ERCC1-118 | European (Germany) | Others | 134 | 5-Fu+leucovorin +oxaliplatin/cisplatin | RR, OS and toxicity |
Ott 2006 [32] | Neoadjuvant chemotherapy for patients with locally advanced GC | TS, MTHFR | European (Germany) | Others | 135 | 5-Fu+cisplatin | RR and OS |
Ott 2011 [33] | Neoadjuvant chemotherapy for patients with locally advanced GC | MTHFR | European (Germany) | Others | 144 | 5-Fu+leucovorin + cisplatin | OS |
Lee 2005 [34] | Patients with advanced GC | TS, MTHFR | Asian (Korea) | NR | 25 | 5-Fu et al. | OS |